Search Results Within Category "Skin Conditions"
A Phase I, Single-Center, Double-Blind, Randomized Safety, Tolerability, and Dermal Reactogenicity Study of Higher Doses of PDC-APB in Healthy Volunteers With a History of Contact Dermatitis Due to Poison Ivy Exposure
Phase 1, Double- Blind Study, 15 week study, Patch test and Vaccine Injection, Males/Females 18-65 years old with history of urushiol exposure. The rash or allergic contact dermatitis of poison ivy is recognized as occurring after the exposure to the urushiol oil which is found in the leaves of poison ivy, oak and sumac. Currently there is no preventative treatment for contact dermatitis. The purpose of this study is to find out if the vaccine, PDC-APB can help with the prevention of contact dermatitis.
Willing to follow all study instructions
Attend all study visits
Positive test result of HIV, Hepatitis B or Hepatitis C
Participation in an investigational drug or device study within 30 days prior to screening
There are over the counter medications that are not permitted during the study participation, the study coordinator will discuss the list during the screening process.
A Multicenter, Open-Label, Single Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Severe Atopic Dermatitis
Atopic Dermatitis: Open Label, 64 weeks study. Injectable medicine. Males/Females 2-11 years with moderate to severe atopic dermatitis. The goal of the study is assess the uptake of the drug by the body and safety of nemolizumab administered with topical corticosteroids.
Participants will attend in person visit at the Dermatology Clinical Trial office. Dr. Zaenglein is the pediatric dermatologist in charge of this research study and will do all skin evaluations. In addition at different time points there will be blood that is drawn, questionnaires to be completed, and ECGs will be performed.
Study coordinator will discuss.
Diagnosed with Moderate to Severe Atopic Dermatitis
Willing to attend all study visits and follow directions
Had a documented asthma exacerbation requiring hospitalization in the past 12 months.
Weigh less than 22 pounds
Defining the cellular and molecular signatures that are associated with the clinical heterogeneity of hidradenitis suppurativa
Patients with the clinical diagnosis of mild, moderate to severe Hidradenditis Suppurativa or normal healthy volunteers ages 18 and older to participate in a 1 time study visit. There is no treatment provided but we may gain information for the treatment of HS.
Eligible participants will attend a one time in person visit. During the visit, the study team will ask you to participate in the following activities: collect skin sample, blood sample and cheek swab. Take photographs of your HS lesions.
study coordinator will discuss.
Hidradentitis Suppurativa diagnosis for 3 months
Normal skin participants
Normal skin participants do not have an autoimmune disease
Participants who do not want to have any of the lesion sampling performed
Reliability and Validity Testing of the Internalized Skin Bias Questionnaire – Revised
Studies have show that patients with skin conditions are often subject to social stigma. Exposure to these negative biases can lead to negative feelings for the patient. This study seeks to evaluate how patients with various skin conditions are impacted by these social biases.
Take an online survey that is expected to take 15-20 minutes. You will be asked to provide your email and take a short (5-10 minute) survey with some of the same questions 72 hours later.
Access to the internet
Must have a skin condition (Hidradenitis Suppurativa, Acne, Psoriasis, Atopic Dermatitis (Eczema), Vitiligo, Cutaneous lupus erythematosus, Rosacea, etc.)
Read/write in English
Those unable to consent
Those without a skin condition
Unable to read/write in English
A randomized, double blind, vehicle-controlled, multicenter Phase II study to evaluate the safety and efficacy of BF-200 ALA (Ameluz) and BF-RhodoLED in the treatment of moderate to severe Acne vulgaris in adults with photodynamic therapy (PDT)
Moderate to Severe Acne Vulgaris: Males/Females 16 years and older. You will receive the study drug with either 1 hour or 3 hours between study drug application and illumination. The purpose of this study is to test the effectiveness and safety of the study drug, used at two different incubation times (time starting with administration of study drug until start of the red light illumination).
Subjects will attend in person visits in the Dermatology Clinical Trial Office. Your length of participation will depend on how your acne responds to the first treatment; the length of participation for 3 treatments will be approximately 25 weeks.Throughout the study at different time points Dr. Zaenglein will evaluate your acne, blood will be drawn, photos will be taken, and questionnaires will need to be completed.
Study Coordinator will discuss during phone screen.
willingness to stop topical facial treatments other than medical cleansers at least 14 days prior to receiving investigational product.
For females must use an adequate and highly effective or two effective methods of contraception throughout the study. Study coordinator will discuss.
For males- beard or other facial hair that might interfere with the study assessments unless subject agrees to be clean-shaven throughout the entire study period.
Certain medications/treatments not allowed during the study; study coordinator will discuss.
Assessing the treatment of scalp conditions in adult patients
This study is aiming to identify the differences in medicated hair care practices amongst adult patients with scalp conditions. Typical treatment for scalp conditions involves the continued use of medicated shampoos; however, hair care practices across all ethnic and racial barriers are different. This could impact the effectiveness of these medicated washes if they are by chance not being used frequently enough. To our knowledge, no research has explored hair care practices and their relationship to dermatological conditions that affect the scalp.
Participants will complete a one-time survey that will take approximately 5-10 minutes.
Access to email and internet
Have sebhorreic dermatitis, sebopsoriasis, dandruff, or psoriasis of the scalp
Any scalp conditions with open wounds or sores
Assessing the impact of post-inflammatory hyperpigmentation on quality of life in people of color
This survey study is looking to see how post-inflammatory hyperpigmentation (PIH) affects quality of life in people with skin of color.
Participants will complete a one-time survey that will ask about post-inflammatory hyperpigmentation.
Experienced/experiencing post-inflammatory hyperpigmentation
Individuals who are not able to understand English
Skin pathophysiology of Hidradenitis Suppurativa
The purpose of this research study is to collect skin samples from volunteers with HS and volunteers with healthy skin. The collected skin samples will be processed and compared to each other to see if there are specific differences in the skin between the HS volunteer group and the healthy skin volunteer group.
Participants will need to come to a one-time, in-person visit where biopsies (small skin samples) will be collected.- For participants with HS: Up to 4 biopsies will be collected - For participants with healthy skin: Up to 2 biopsies will be collected
HS lesions present in the armpits and/or groin
Certain medications are not allowed in this study- the study team will provide details
Exploratory Trial of Ruxolitinib 1.5% Cream for Early Stage Hidradenitis Suppurativa
Explore all stages of Hidradenitis Suppurativa with a topical medication.
There will be 7 in-person visits and 1 follow-up phone call over a 33 week period. Over the course of the study, the following study procedures will take place: medical history and medication history collection, ECG, lab tests (both blood and urine), photography, skin exams, physical exams, questionnaires, and skin biopsies.
Up to $350
Must have active HS in at least 1 area
Must have negative TB screening assessment
Certain medications can be continued if on stable dose; study coordinator will discuss further.
Pregnant (or considering becoming pregnant) or lactating females
Does not have reliable internet access for weekly electronic surveys
Incidence Rates of Hair Loss in Women Who Wear Hijab
The aim of this study is to obtain information regarding the incidence of hair-related concerns in women who wear hijab and to collect information pertaining to factors that could contribute to hair loss in women who wear the hijab.
This survey study will involve a one-time survey that will take 5-10 minutes.
Women
Read and understand English
Ages 18 years and older
A Randomized, Double-Blind, Placebo-controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Moderate to Severe Hidradenitis Suppurativa
This study is a placebo-controlled study testing the effectiveness and safety of a new drug (izokibep) in adults with hidradenitis suppurativa (HS). HS is a condition where painful skin lesions occur, most often in places on the body where there is friction (ex: armpits, under the breasts, buttocks, and groin). These lesions can drain and scar and will often reoccur.
For this study, participants will come to the study site about 17 times over approximately 59 weeks. During these visits, there will information about medical history and medications collected as well as demographic information, physical and skin exams, vital signs, blood and urine lab testing, ECGs, a chest x-ray, questionnaires, and a daily diary.
HS in at least 2 body sites
Willingness to follow study rules and instructions of study staff
Chronic pain not associated with HS
History of HIV
Hidradenitis Suppurativa: Evaluation of Upadacitinib in Adult and Adolescent Subjects
Phase 3, global, randomized, double-blind, placebo-controlled, multi-center study that will evaluate upadacitinib in the treatment of moderate to severe HS in adult and adolescent subjects who have failed to respond to or are intolerant of ant-TNF therapy and/or 1 approved non-anti-TNF-biologic therapy for HS.This study is comprised of a 35-day screening period, a 16 week placebo-controlled, double-blinded treatment period (Period 1), a 20-week re-randomized extension treatment period (Period 2), a 68-week long-term extension treatment period (Period 3) and a 30-day follow-up period.
You will completed 3 study periods over approximately 104 weeks. During that time at different time points you will have your skin examined, ECG, complete questionnaires, and have your labs drawn. In addition you will take the study medication as directed by the research study coordinators.
2 active HS areas
History of previous use ≥ 1 TNF inhibitor for at least 12 weeks and/or 1 approved non-anti-TNF biologic therapy for HS for at least 16 weeks - study coordinator will discuss
Must agree to use daily wash
A Multicenter, Randomized, Double-blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Patidegib Gel 2% for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects with Gorlin Syndrome
Participants 18 years and older who meet the diagnostic criteria for the basal cell nevus (Gorlin) syndrome will be assigned to receive either Patidegib Gel 2% or Placebo (no active medicine) to apply twice daily for 12 months. The assignment will be made according to sex assigned at birth, age, and number of BCC lesions at the treatment area at Baseline. The primary endpoint is a comparison between the 2 treatment arms of the number of new BCCs at Month 12 compared to Baseline. The BCCs will be imaged and tracked consistently throughout the study to identify new BCCs and to confirm their diagnosis by dermoscopy (handheld instrument with a 15x magnification lens and a cross-polarized light source).
Participants will participate in 15 visits over approximately 14 months (attend 6 in person visits along with 9 phone call visits). In addition, participants will receive study medication to apply twice a day for 12 months and undergo clinical tests at various time points, which include blood tests, ECG, complete questionnaires/diary, skin exam and skin photographs.
Compensation is provided for eligible participants.
Diagnostic criteria present for Gorlin Syndrome
10 BCCs present on face at Randomization (Baseline/Day 1)
uncontrolled systemic disease
uncontrolled skin disease on the face.
SELVA: A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of PTX-022 in the Treatment of Microcystic Lymphatic Malformations
Microcystic lymphatic malformations (mLMs) are masses of spongy tissue that may have small fluid-filled cysts. They are made of abnormally large or misshapen lymph vessels that do not work correctly. They are usually present at birth and get worse over time. Complications of mLMs include infection, bleeding, leaking of lymphatic fluid, disfigurement, and impaired mobility. The purose of this study is to find out if the study medicine, sirolimus 3.9% topical gel, can help with the treatment of mLMs.
Total duration of the study is approximately 28 weeks, with up to 8 visits (approximately 1 visit per month). 5 visits will occur in person and 3 visits will be phone call visits. You will also complete 2 interviews.Procedures involved in the study include: medical history collection, physical exams, skin assessments, patient interviews, photographs, blood draws (at up to 3 visits), urine tests, and questionnaires.
At least 6 years old
Willing to follow all study guidelines
History of HIV or other immunodeficiency